HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- (3- methoxyphenyl)- 3- (5- methyl- 1,2,4- oxadiazol- 3- yl)- 2- oxo- 1,2- dihydro- 1,6- naphthyridine

a cognitive enhancer; structure in first source does not agree with name

Also Known As:

AC 3933; AC-3933; AC3933

Networked: 4 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-1,2-dihydro-1,6-naphthyridine: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Naphthyridines: 2
      - 5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-1,2-dihydro-1,6-naphthyridine: 4

Experts

1.	Hashimoto, Takashi: 2 articles (05/2016 - 12/2014)
2.	Hashimoto, T: 2 articles (04/2014 - 01/2014)
3.	Kiyoshi, T: 2 articles (04/2014 - 01/2014)
4.	Kohayakawa, H: 2 articles (04/2014 - 01/2014)
5.	Yoshida, N: 2 articles (04/2014 - 01/2014)
6.	Iwamura, Yoshihiro: 1 article (05/2016)
7.	Hatayama, Yuki: 1 article (12/2014)
8.	Nakamichi, Keiko: 1 article (12/2014)
9.	Yoshida, Naoyuki: 1 article (12/2014)
10.	Hatayama, Y: 1 article (04/2014)

Related Diseases

1.	Cognitive Dysfunction 01/03/2014 - "These results indicate that AC-3933, a potent and selective BzR inverse agonist with low intrinsic activity, might be useful in the treatment of cognitive disorders associated with degeneration of the cholinergic system." 05/01/2016 - "AC-3933, a novel benzodiazepine receptor partial inverse agonist, is a drug candidate for cognitive disorders including Alzheimer's disease. " 05/01/2016 - "We have previously reported that AC-3933 enhances acetylcholine release in the rat hippocampus and ameliorates scopolamine-induced memory impairment and age-related cognitive decline in both rats and mice. "
2.	Alzheimer Disease (Alzheimer's Disease) 04/18/2014 - "These findings indicate that AC-3933 with its low risk for side effects may be useful in the treatment of Alzheimer's disease. " 04/18/2014 - "In this study, we evaluated AC-3933 potential for the treatment of Alzheimer's disease, a disorder characterized by progressive decline mainly in cholinergic function. " 04/18/2014 - "In vivo pharmacological characterization of AC-3933, a benzodiazepine receptor partial inverse agonist for the treatment of Alzheimer's disease." 05/01/2016 - "AC-3933, a novel benzodiazepine receptor partial inverse agonist, is a drug candidate for cognitive disorders including Alzheimer's disease. "
3.	Memory Disorders (Memory Loss) 05/01/2016 - "Taken together, these results indicate that AC-3933 improves memory deficits caused by both cholinergic and glutamatergic hypofunction and suggest that the ameliorating effect of AC-3933 on MK-801-induced memory impairment is mediated by a mechanism other than inverse activation of the benzodiazepine receptor. " 12/15/2014 - "In scopolamine-treated mice, both AC-3933 and donepezil significantly ameliorated memory deficits in the Y-maze test at doses of 0.3-3 mg/kg and 10-15 mg/kg, respectively. " 12/15/2014 - "We have previously reported that AC-3933, a newly developed benzodiazepine receptor partial inverse agonist, facilitates acetylcholine release in the hippocampus and ameliorates scopolamine-induced memory deficits in rats. " 05/01/2016 - "Interestingly, the procognitive effects of AC-3933 on MK-801-induced memory impairment were not affected by the benzodiazepine receptor antagonist flumazenil, although this was not the case for the beneficial effects of AC-3933 on scopolamine-induced memory deficit. "
4.	Amnesia (Dissociative Amnesia) 05/01/2016 - "AC-3933, a benzodiazepine partial inverse agonist, improves memory performance in MK-801-induced amnesia mouse model." 04/18/2014 - "Oral administration of AC-3933 (0.01-0.03mg/kg) resulted in the amelioration of scopolamine-induced amnesia, as well as a shift in electroencephalogram (EEG) relative power characteristic of pro-cognitive cholinergic activators, such as donepezil. "

Related Drugs and Biologics

1.	Scopolamine (Hyoscine)
2.	Acetylcholine (Acetylcholine Chloride)
3.	Cholinergic Agents (Cholinergics)
4.	GABA-A Receptors (GABA(A) Receptor)
5.	Donepezil (Aricept)
6.	Flumazenil (Romazicon)
7.	Benzodiazepines

Related Therapies and Procedures

1.	Oral Administration